Study S000828

Comparative Investigation of Changes in Body Composition and Bone Turnover Markers in People With Obesity After Treatment With Tirzepatide Versus Liraglutide. A Prospective Cohort Study.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07094568
Acronym: TiLi-BONE
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 72
Start: 2025-05-23
Primary completion: 2026-12-30
Lead sponsor: National and Kapodistrian University of Athens
Conditions: Obesity (Disorder)
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in serum CTX concentration [Baseline and 3 months after intervention initiation]

Linked records (10)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0044966	EP560 - ECE_2371 - Muscle function in adults with class III obesity receiving liraglutide vs tirzepatide Maria Evangelia Koloutsou, European Journal of Endocrinology	2026	Nonrandomized study	DOI	cites ClinicalTrials.gov:NCT07094568
R0045388	EP670 - ECE_2372 - Liraglutide versus tirzepatide: real-world effects on lipid and carbohydrate metabolism in adults with class III obesity Maria Evangelia Koloutsou, European Journal of Endocrinology	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT07094568
R0004681	Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice. Lv F, Pharmaceuticals (Basel, Switzerland)	2024	Preclinical	PMID 39770498 DOI	registry reference RESULT:39770498
R0029122	The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Stefanakis K, Metabolism: clinical and experimental	2024	Narrative review	PMID 39481534 DOI	registry reference RESULT:39481534
R0007016	Effect of Liraglutide on Osteoporosis in a Rat Model of Type 2 Diabetes Mellitus: A Histological, Immunohistochemical, and Biochemical Study. Fathy MA, Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada	2023	Preclinical	PMID 37832035 DOI	registry reference RESULT:37832035
R0013092	Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway. Cheng Y, BMC musculoskeletal disorders	2022	Preclinical	PMID 35581617 DOI	registry reference RESULT:35581617
R0012194	Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial. Hygum K, Bone	2020	Randomized trial	PMID 31870634 DOI	registry reference RESULT:31870634
R0024908	Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis. Yang L, Journal of endocrinological investigation	2019	Preclinical	PMID 30955181 DOI	registry reference RESULT:30955181
R0013061	Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis. Wen B, Experimental and therapeutic medicine	2018	Preclinical	PMID 29805533 DOI	registry reference RESULT:29805533
R0016229	GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. Iepsen EW, The Journal of clinical endocrinology and metabolism	2015	Randomized trial	PMID 26043228 DOI	registry reference RESULT:26043228